The oral oxazolidinone antibiotic targets infections due to multi-drug resistant gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). MicuRx president and chief executive officer Zhengyu
Flutiform is a fixed-dose combination long-acting beta-agonist, formoterol fumarate and the prescribed corticosteroid, fluticasone propionate, designed for treating asthma patients. Flutiform uses SkyePharma’s patented SkyeDry formulation technology which
The OTC products being divested include Phillips MOM, Solpadeine, Dequadin, Cartia and Zantac. The deal follows agreements reached in December 2011 and last month to divest the brands
The intravenous (IV) iron therapy, indicated for the treatment of IDA in adult patients with chronic kidney disease (CKD), will be marketed as Rienso in the European Union
The recommendation by the CHMP of the EMA for approval of ruxolitinib to treat of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post-polycythemia vera myelofibrosis
The RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia utilized Tekmira’s lipid nanoparticle (LNP) technology. Tekmira president and CEO Mark Murray said the new data from
ACY-1215T is at present being investigated in human trials to treat multiple myeloma. Acetylon chief executive officer Walter Ogier said, "Given the widespread interest in the development of
The Sevikar, a fixed dose combination of olmesartan medoxomil and amlodipine besylate tablets, is likely to be included on the national lists of compensated drugs. The combination will
The patent covers a core element of Rosetta’s microRNA technology in the development of cancer therapeutics associated with p53-negative cancers. Rosetta Genomics president and chief executive officer Kenneth
Adimab also announced the achievement of technical milestones from its ongoing collaborations with Novartis, Merck, Merrimack, and Genentech. Adimab CEO Tillman Gerngross said, "We are now expanding our
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.